Back

Prevalence, clinical characteristics, and prognostic impact of frailty in patients undergoing implantable cardioverter defibrillator or cardiac resynchronization therapy

13 April 2026 (08:00 - 18:15)
Organised by: Logo
Congress Presentation Part of: Poster session (2): device therapy Implantable Cardioverter-Defibrillator (ICD) EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Assistant Professor Yoshihisa Naruse

Hamamatsu University School of Medicine, Hamamatsu (Japan)

210 More presentations in this session

Presentation thumbnail
Genetic variants and device upgrade in young pacemaker recipients
Doctor J. Sanchez Moreno (Almeria, ES)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic repolarization changes following conduction system pacing in pacemaker-induced cardiomyopathy
Doctor A. Sahin (Konya, TR)
Abstract Slides Video
Presentation thumbnail
Experiences with implantable loop recorders in syncope patients
Mr A. Oinonen (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Forcecardiography as a non-invasive predictor of echocardiographic parameters in patients undergoing cardiac resynchronization therapy: a preliminary study
Doctor V. Pergola (Naples, IT)
Abstract
Presentation thumbnail
Diagnostic work-up and clinical characteristics in out-of-hospital cardiac arrest survivors with ICD implantation: a prospective Danish study
Mr C. Hansen (Copenhagen, DK) Doctor B. Winkel (Copenhagen, DK)
Abstract

Access the full session

Session thumbnail
Poster session (2): device therapy

The Event

Event poster

EHRA 2026

13 April 2026 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Clinical impact of frailty after durable left ventricular assist device implantation
thumbnail
Congress Presentation
Prevalence and prognostic implications of frailty and other geriatric conditions in patients with transthyretin amyloid cardiomyopathy. The AMYLO-FRAIL study.
thumbnail
Congress Presentation
Frailty and bleeding events in patients with heart failure: Insights from the JROADHF-NEXT

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources